危重症患者的膈肌无力:基本机制揭示治疗机会
本文为综述,聚焦危重症患者膈肌无力的细胞机制。文中指出很大比例危重症患者存在显著膈肌无力,且与不良临床结局相关;机械通气使用和脓毒症是两大最主要危险因素。膈肌产力下降由收缩力缺陷和膈肌肌肉量减少共同导致,且机械通气与脓毒症相关膈肌功能障碍涉及许多相同的分子机制。综述梳理了目前识别的位于二者交汇处的关键细胞机制,并探讨通过治疗性调控这些最终共同通路靶点来治疗或预防危重症膈肌无力的潜力。
要点
- 很大比例危重症患者存在显著膈肌无力,且与不良临床结局相关。
- 危重症膈肌无力两大最主要危险因素为使用机械通气和存在脓毒症。
- 膈肌产力下降由收缩力缺陷与膈肌肌肉量减少共同导致。
- 机械通气与脓毒症相关膈肌功能障碍涉及许多相同的分子机制。
- 综述探讨通过治疗性调控这些最终共同通路靶点来治疗或预防膈肌无力的潜力。
适用人群与场景
- 危重症患者,尤其是接受机械通气者和存在脓毒症者。
研究设计与关键结果
- 综述指出,很大比例危重症患者存在显著膈肌无力,并与不良临床结局相关。
- 膈肌无力的两大最主要危险因素为使用机械通气和存在脓毒症。
- 上述条件下膈肌产力下降由收缩力缺陷和膈肌肌肉量减少共同导致。
- 机械通气与脓毒症相关膈肌功能障碍涉及许多相同的分子机制。
- 综述梳理了目前识别的位于机械通气与脓毒症交汇处的关键细胞机制,并探讨通过治疗性调控这些最终共同通路靶点来治疗或预防危重症膈肌无力的潜力。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「对床旁实践的改变」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
The diaphragm is the primary muscle of inspiration. Its capacity to respond to the load imposed by pulmonary disease is a major determining factor both in the onset of ventilatory failure and in the ability to successfully separate patients from ventilator support. It has recently been established that a very large proportion of critically ill patients exhibit major weakness of the diaphragm, which is associated with poor clinical outcomes. The two greatest risk factors for the development of diaphragm weakness in critical illness are the use of mechanical ventilation and the presence of sepsis. Loss of force production by the diaphragm under these conditions is caused by a combination of defective contractility and reduced diaphragm muscle mass. Importantly, many of the same molecular mechanisms are implicated in the diaphragm dysfunction associated with both mechanical ventilation and sepsis. This review outlines the primary cellular mechanisms identified thus far at the nexus of diaphragm dysfunction associated with mechanical ventilation and/or sepsis, and explores the potential for treatment or prevention of diaphragm weakness in critically ill patients through therapeutic manipulation of these final common pathway targets.
参考来源
- Petrof BJ. Diaphragm Weakness in the Critically Ill: Basic Mechanisms Reveal Therapeutic Opportunities. Chest. 2018. PMID: 30144420. doi:10.1016/j.chest.2018.08.1028
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。